Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128628 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
- 20
- Study locations
NCT07128628: Recruiting Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
NCT07128628 is a Phase 2 study of Dry Eye Disease that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 423 participants, above the 242-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128628, a Phase 2 study of Dry Eye Disease, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
- DRUG Lifitegrast
- DRUG Perfluorohexyloctane
Study Locations (20)
California
- Global Research Management, Inc. - Glendale
- SoCal Eye - Lakewood Clinic - Long Beach
- LoBue Laser and Eye Medical Center - Murrieta
- Eye Research Foundation, Inc. - Newport Beach
- Wolstan and Goldberg Eye Associates - Torrance
Missouri
- Insight Eyecare Specialties, Inc. - Kansas City
- Moyes Eye Center, P.C. - Kansas City
- Ophthalmology Consultants, Ltd. - St Louis
- Comprehensive Eye Care Ltd. - Washington
Florida
- Segal Drug Trials/Office of Bruce A Segal, MD - Delray Beach
- Bowden Eye and Associates - Jacksonville
- Shettle Eye Research, Inc - Largo
Minnesota
- Vance Thompson Vision - Alexandria - Alexandria
- Complete Eye Care of Medina - Medina
New York
- Opthalmic consultants of Long Island - Garden City
- Rochester Ophthalmological Group,PC - Rochester
Arizona
- Eye Doctors of Arizona, PLLC - Phoenix
Georgia
- Clayton Eye Clinical Research, LLC - Morrow
Indiana
- Midwest Cornea Associates LLC - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07128628 shows while recruiting
NCT07128628 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, above the 242-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT07128628 names 20 study sites across 9 states, led by California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT07128628 about?
NCT07128628 is a clinical study titled "A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease". A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
What is the current status of trial NCT07128628?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2025-10-24. Estimated completion is 2026-11.
What conditions does trial NCT07128628 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07128628?
The interventions under investigation include: Vehicle (DRUG), Lifitegrast/Perfluorohexyloctane Fixed Dose Combination (DRUG), Lifitegrast (DRUG), Perfluorohexyloctane (DRUG).
Who is sponsoring clinical trial NCT07128628?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128628 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07128628's enrollment target sits among peer trials
423 6th of 33 higher than 28 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
- NCT06978127 · 424 participants · NA
Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI